• We present, to our knowledge, the first case of Cushing's syndrome due to large doses of intramuscular dexamethasone acetate. Dexamethasone levels after intramuscular dexamethasone administration were measured in two patients. Serial determination of the dexamethasone levels demonstrated prolonged serum half-lives of seven and 33 days in the two patients, respectively. Furthermore, pharmacologic levels of dexamethasone were present as long as seven months after the initial injections. The present recommendation for the use of intramuscular dexamethasone acetate is as frequent as every one to three weeks. However, our patients demonstrate that supraphysiologic levels of dexamethasone may still be present well beyond the three-week period.
(Arch Intern Med 1986;146:1848-1849)
Hughes JM, Hichens M, Booze GW, Thorner MO. Cushing's Syndrome From the Therapeutic Use of Intramuscular Dexamethasone Acetate. Arch Intern Med. 1986;146(9):1848–1849. doi:10.1001/archinte.1986.00360210246041
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: